FilingSEC EDGAR10-K
Aytu BioPharma Reports Fiscal 2026 Results and Business Restructuring
· SEC accepted
StageAnnual Report Filing
Filing content
The company reported a net loss of $14.3 million for fiscal 2026 and is pursuing cost-saving measures through the termination of a license agreement.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…